- Home
- GENK vs AXDX Comparison
GENK vs AXDX Comparison
Compare GENK & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- AXDX
- Stock Information
- Founded
- GENK 2011
- AXDX 1982
- Country
- GENK United States
- AXDX United States
- Employees
- GENK N/A
- AXDX N/A
- Industry
- GENK Restaurants
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- GENK Consumer Discretionary
- AXDX Industrials
- Exchange
- GENK Nasdaq
- AXDX Nasdaq
- Market Cap
- GENK 41.1M
- AXDX 41.8M
- IPO Year
- GENK 2023
- AXDX 1996
- Fundamental
- Price
- GENK $7.53
- AXDX $1.16
- Analyst Decision
- GENK Strong Buy
- AXDX Hold
- Analyst Count
- GENK 3
- AXDX 1
- Target Price
- GENK $13.17
- AXDX $1.00
- AVG Volume (30 Days)
- GENK 60.0K
- AXDX 72.5K
- Earning Date
- GENK 11-12-2024
- AXDX 11-07-2024
- Dividend Yield
- GENK N/A
- AXDX N/A
- EPS Growth
- GENK 483.78
- AXDX N/A
- EPS
- GENK 0.17
- AXDX N/A
- Revenue
- GENK $198,834,000.00
- AXDX $11,909,000.00
- Revenue This Year
- GENK $14.66
- AXDX $1.50
- Revenue Next Year
- GENK $21.47
- AXDX $4.17
- P/E Ratio
- GENK $43.70
- AXDX N/A
- Revenue Growth
- GENK 12.50
- AXDX N/A
- 52 Week Low
- GENK $5.61
- AXDX $0.73
- 52 Week High
- GENK $14.46
- AXDX $4.41
- Technical
- Relative Strength Index (RSI)
- GENK 39.46
- AXDX 27.10
- Support Level
- GENK $7.10
- AXDX $1.12
- Resistance Level
- GENK $8.45
- AXDX $1.27
- Average True Range (ATR)
- GENK 0.51
- AXDX 0.13
- MACD
- GENK -0.08
- AXDX -0.03
- Stochastic Oscillator
- GENK 22.22
- AXDX 5.26
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.